Fred Alger Management released its fourth-quarter 2025 investor letter, noting the US equity market’s strong finish. The S&P surged 2.7%, driven by positive corporate earnings and the Fed’s interest rate stance. The Alger Small Cap Focus Fund outperformed the Russell 2000 Growth Index in Q4 2025, with the Utilities and Financials sectors contributing to performance.

Exact Sciences Corporation (NASDAQ:EXAS) was highlighted in the investor letter, showing positive growth. The stock closed at $102.43, with a one-month return of 0.60%. Exact Sciences Corporation (NASDAQ:EXAS) has a market capitalization of $19.453 billion and gained 97.97% over the past 52 weeks.

Alger Small Cap Focus Fund praised Exact Sciences Corporation (NASDAQ:EXAS) for its oncology testing products, notably Cologuard. The stock price rose after an acquisition announcement by Abbott for approximately $21 billion. Exact Sciences Corporation (NASDAQ:EXAS) is among billionaire George Soros’ small-cap stocks with high potential.

While Exact Sciences Corporation (NASDAQ:EXAS) is not in the top 30 stocks among hedge funds, it remains a solid investment option. The company is seen as having potential, but some AI stocks may offer greater upside with lower risk. For more insights, explore hedge fund investor letters from Q4 2025 and articles on market trends and stock analysis.

Read more at Yahoo Finance: Exact Sciences (EXAS) Rose Following the Acquisition Announcement by Abbott